This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "p

Executes Agreement to Acquire Hartlab, a Chicago-Area CLIA-Certified Clinical

Intended to Complete June 30, 2009

ARBOR, MI--(MARKET WIRE)-June 1, 2009 -- Adeona Pharmaceuticals, Inc.

specialty pharmaceutical company dedicated to the awareness, diagnosis,

prevention and treatment of subclinical zinc deficiency and chronic copper

toxicity in the mature population, today announced that it has entered into an

agreement to acquire Hartlab LLC, an independent Chicago-area CLIA-certified

clinical laboratory ("Hartlab").

16, 2009 Adeona announced its agreement to potentially acquire Colwell Clinical

Laboratories located in Santa Ana, California for a purchase price of

$825,000. The closing date for such acquisition was intended to be

May 31, 2009. Adeona has been exploring the potential integration of

operations between the two companies while also evaluating other

opportunities. On the basis of more favorable logistics relative to

Adeona's Ann Arbor location and cost, Adeona has determined to permit the

Colwell acquisition agreement to expire and on May 30, 2009 instead entered into

an agreement to acquire Hartlab, a Chicago-area CLIA certified clinical

laboratory for a cash purchase price of $280,000. The transaction is

expected to close on or before June 30, 2009.

in 2006 and located in Bolingbrook, Illinois, Hartlab can serve the same-day

clinical laboratory needs of physicians that care for the approximately 9

million residents of the greater Chicago area and can currently provide next-day

clinical laboratory services to physicians in most states other than California,

New York and Florida.

is a licensed Medicare and Medicaid provider, and accepts insurance from most

third party reimbursers as well as private payers.

intends Hartlab to remain independent but to assist Hartlab in expanding its

offering of services to include a suite of high precision and proprietary assays

and diagnostic panels useful for the diagnosis, prevention and treatment of

conditions that involve metal dyshomeostasis. Adeona believes that, if operated

as planned, Hartlab may satisfy an unmet physician need for a clinical

laboratory dedicated and competent in such areas.

Kanzer, CPA, JD, Chairman and CEO of Adeona, stated, "While we look forward to

the opportunity to potentially enter the substantial California market in the

future, at the present time, we determined that Hartlab's proximity to Ann Arbor

and access to the greater Chicago market would be better suited to the

management of our current metal dyshomeostasis clinical diagnostic service

2007 and 2008, Adeona sponsored and conducted an IRB-approved, prospective,

observational, blinded clinical trial enrolling 90 subjects, 30 with Alzheimer's

disease (AD), 30 with Parkinson's disease (PD) and 30 age-matched normal

subjects. The purpose of the study

evaluate serum markers of copper status and compare these results across the

three groups of patients. The results of our study indicate highly statistically

significant differences in serum markers of copper status between Alzheimer's

and normal subjects. We believe that the differences observed suggest that

Alzheimer's patients have impaired protection from chronic copper toxicity,

which may contribute to the progression of their disease. The results from this

study also appear to indicate a subclinical zinc deficiency in Alzheimer's

subjects. Results from the study also indicate that it may be useful to screen

the existing Parkinson's disease population for signs of Wilson's disease, an

effort that Adeona hopes to promote and accomplish through Hartlab. Adeona and

its HealthMine subsidiary intend to announce the results from this study in the

first half of next month and launch a panel of metal dyshomeostasis diagnostic

products and services thereafter.

Proposed Acquisition

acquisition is expected to be completed on or before June 30, 2009 and is

subject to satisfactory due diligence on the part of Adeona. Adeona has paid a

non-refundable deposit of $14,000 and will pay an additional $266,000 at closing

on or before June 30, 2009 in exchange for all of the issued and outstanding

membership interests of Hartlab. Adeona intends to maintain the

operations and employees of Hartlab and is also requiring that the current

owner/founder enter into a consulting agreement to assist in the transition and

operation of the company for a period of time.

Adeona Pharmaceuticals, Inc.

Pharmaceuticals, Inc. (AMEX:AEN - News) is a specialty

pharmaceutical company dedicated to the awareness, diagnosis, prevention and

treatment of subclinical zinc deficiency and chronic copper toxicity in the

mature population. Adeona believes that such conditions may contribute to the

progression of debilitating degenerative diseases, including, Dry Age-Related

Macular Degeneration (Dry AMD), Alzheimer's disease (AD) and mild cognitive

impairment (MCI) in susceptible persons. Adeona is also developing a number of

late-stage clinical drug candidates for the treatment of rheumatoid arthritis

and multiple sclerosis. For further information, please visit www.adeonapharma.com.

Inc., a subsidiary of Adeona Pharmaceuticals Inc., is a health education

communication and information resource company dedicated to raising awareness of

subclinical zinc deficiency and the risks of chronic copper toxicity in the

mature population. HeathMine currently hosts two Web 2.0 websites, www.healthmine.com

and the recently launched www.copperproof.com,

a new informational website dedicated to increasing awareness of the potential

health effects of chronic copper toxicity, especially in the mature population.

By visiting www.copperproof.com,

users can view a brief informational video, review relevant literature, obtain a

sensitive test card to test their tap water for copper and, should they wish to

participate in HealthMine's CopperProof National Tap Water Survey, share their

levels of copper in tap water and geographically compare such levels to those of

others. Since 2003, an increasing body of research continues to implicate

chronic copper exposure as a potential factor that may contribute to the

progression of diseases of the mature population, especially Alzheimer's

release includes forward-looking statements on Adeona's current expectations and

projections about future events. In some cases forward-looking statements can be

identified by terminology such as "may," "should," "potential," "continue,"

"expects," "anticipates," "intends," "plans," "believes," "estimates," and

similar expressions. These statements are based upon current beliefs,

expectations and assumptions and are subject to a number of risks and

uncertainties, many of which are difficult to predict and include statements

regarding designing additional clinical trials for oral dnaJP1, Zinthionein,

flupirtine, or Trimesta. Adeona is at an early stage of development and may not

ever have any products that generate significant revenue. Important factors that

could cause actual results to differ materially from those reflected in Adeona's

forward-looking statements include, among others, a failure of Adeona's product